Appendix Table A2.
Descriptive data for all study variables
| Current oncologist† | First-year oncologist ‡ | |||
|---|---|---|---|---|
| Non-integrated (N=77,159) |
Integrated (N=4,740) |
Remained non-integrated (N=49,124) |
Integrated in later years (N=3,216) |
|
| Mean (Standard Deviation) or % | Mean (Standard Deviation) or % | |||
| Variable | ||||
| Patient characteristics | ||||
| Age | 73.59(8.65) | 73.79(8.64) | 73.08(8.62) | 72.77(8.53) |
| Female (%) | 51.73% | 51.86% | 51.71% | 52.21% |
| White (%) | 87.57% | 87.85% | 87.43% | 88.06% |
| Having diabetes (%) | 15.10% | 15.17% | 15.73% | 14.33% |
| Having hypertension (%) | 30.44% | 30.72% | 30.91% | 29.63% |
| Having ischemic heart disease (%) | 68.23% | 66.22% | 69.98% | 67.26% |
| Having hyperlipidemia (%) | 39.61% | 38.92% | 39.99% | 37.25% |
| Having depression (%) | 50.69% | 50.53% | 52.24% | 52.64% |
| Having congestive heart failure (%) | 16.75% | 19.60% | 17.35% | 17.07% |
| Having cataract (%) | 20.28% | 19.28% | 20.30% | 16.48% |
| Having COPD‡ (%) | 21.73% | 23.71% | 20.98% | 22.48% |
| Number of chronic conditions | 23.36% | 20.57% | 25.74% | 19.34% |
| Metastasis (%) | 4.60(2.61) | 4.60(2.62) | 4.68(2.59) | 4.39(2.51) |
| Cancer type | ||||
| Breast (%) | 32.13% | 40.70% | 30.29% | 33.05% |
| Prostate (%) | 22.05% | 24.30% | 21.73% | 23.54% |
| Lung (%) | 22.20% | 26.03% | 20.44% | 24.84% |
| Colon (%) | 21.27% | 16.79% | 24.29% | 16.73% |
| Leukemia (%) | 15.11% | 14.07% | 15.20% | 14.09% |
| Lymphoma (%) | 7.08% | 9.77% | 6.76% | 10.07% |
| Measured at the Zip level | ||||
| Percent Unemployed | 8.88(4.06) | 9.08(4.25) | 8.85(4.08) | 8.69(4.13) |
| Median income($) | 57,042(23,181) | 58,206(23,310) | 56,521(22,876) | 57,897(23,653) |
| Percent college educated among 65 years and over | 21.10(13.30) | 22.01(14.01) | 20.76(13.19) | 21.15(13.70) |
| Chemotherapy outcomes | ||||
| Frequency of chemotherapy drug claims | 11.73(11.63) | 9.14(9.51) | 11.48(10.95) | 9.39(9.77) |
| Frequency of chemotherapy administration claims | 15.52(16.72) | 12.24(13.63) | 14.97(15.69) | 12.32(13.78) |
| Chemotherapy drug spending ($) | 18,626(25,256) | 19,228(26,729) | 16,413(23,168) | 18,313(26,705) |
| Chemotherapy administration spending ($) | 1,906(2,118) | 2,030(2,843) | 1,871(2,021) | 1,884(2,486) |
| Chemotherapy drug spending per claim ($) | 1,819(2,489) | 2,507(3,655) | 1,613(2,208) | 2,325(6,265) |
| Dosage-adjusted chemotherapy outcomes | ||||
| Frequency of dosage-adjusted chemotherapy drug claims | 12.0(15.32) | 10.97(48.48) | 12.13(14.41) | 10.79(15.45) |
| Chemotherapy drug spending per dosage-adjusted claim ($) | 1,964(8,898) | 2,685(6,034) | 1,783(9,948) | 2,313(4,677) |
Note:
†
Comparison of patient characteristics by the integration status of the patient’s oncologist in a given year;
‡
Comparison of patient characteristics only in the first year when the patient was included in the sample based on the whether the patient’s first-year oncologist integrated with a hospital in later years.